In another year of considerable turbulence for pharmaceuticals, with COVID-19 continuing to disrupt business strategies and patient access to medicines, regulators and companies alike are finding ways to keep the approval flow coming. The trend for 2021 new drug approvals in both the US and the European Union, the two most important launching pads for innovative medicines worldwide, has more than kept pace with 2020.
